AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00050609
Drug: tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg tadalafil tablet taken by mouth once a day for 8 weeks
Trial: NCT00050609
Drug: tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg tadalafil tablet taken by mouth once a day for 8 weeks
Trial: NCT03116698
Drug: Low dose DFD07 once daily
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low dose DFD07 once daily
Trial: NCT01281865
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT01281865
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT03001089
Drug: Oral Fludrocortisone (enteral)
DrugBank: Fludrocortisone (DB00687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Fludrocortisone (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
Trial: NCT01483781
Drug: Canagliflozin
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Type = exact number, unit = mg, number = 300, form = capsule, route = oral use. One encapsulated tablet once daily for up to approximately 85 days (approximately 12 weeks)
Trial: NCT01803321
Drug: rilonacept (IL-1 Trap)
RxNorm normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01003210
Drug: Hyland's earache drops
RxNorm normalized name: Belladonna/Calcarea Carbonica/Chamomile/Clubmoss/Pulsatilla/Sulfur 30 C-30 C-30 C-30 C-30 C-30 C Otic Solution [HYLAND'S EARACHE DROPS]
DrugBank: Belladonna (DB13913)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-4 drops in affected ear 3 times a day as needed for up to 5 days
Trial: NCT01222455
Drug: Fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral tablets, single dose
Trial: NCT02858908
Drug: Tideglusib
RxNorm normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tideglusib for oral suspension,
Trial: NCT00432614
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00003398
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04360551
Drug: Telmisartan 40mg
RxNorm normalized name: TELMISARTAN 40MG TAB
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Angiotensin Receptor Blocker (ARB)
Trial: NCT03516526
Drug: Natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Extending dose intervals of natalizumab from 4 weeks to maximum of 8 weeks based on trough natalizumab concentrations
Trial: NCT00520884
Drug: Ghrelin Infusion - Frail
RxNorm normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min will be infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
Trial: NCT01270308
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole DR Capsules 30 mg
Trial: NCT01490099
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One single dose of insulin detemir produced by current process and the NN729 process injected subcutaneously on two separate dosing visits in varying order
Trial: NCT03637556
Drug: DST-0509
RxNorm normalized name: DST
DrugBank: Dihydrostreptomycin (DB11512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel iron chelator with improved absorption characteristics
Trial: NCT03637556
Drug: Jadenu
RxNorm normalized name: Jadenu
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Commercial iron chelator with standard absorption characteristics
Trial: NCT00766038
Drug: Recombinant human Growth Hormone
RxNorm normalized name: Recombinant human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micrograms/day SC for 6 months. Dose adjusted based on serum IGF-1 measurements
Trial: NCT03637556
Drug: Exjade
RxNorm normalized name: Exjade
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Commercial iron chelator with standard absorption characteristics
Trial: NCT03161054
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Maintenance Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Post Maintenance Phase: vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).
Trial: NCT00933179
Drug: EE/Levonorgestrel (Microgynon, BAY86-4977)
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 3 cycles
Trial: NCT02152332
Drug: JNJ-54861911 - Supratherapeutic Dose
RxNorm normalized name: JNJ-54861911
DrugBank: Atabecestat (DB15307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.
Trial: NCT02152332
Drug: JNJ-54861911-Matched Placebo
RxNorm normalized name: JNJ-54861911
DrugBank: Atabecestat (DB15307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.
Trial: NCT04125550
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-3 mg/kg propofol will be administered for anesthesia induction. 10 mg/ kg/h propofol infusion will be administered for the maintenance of anesthesia.
Trial: NCT04125550
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sevoflurane inhalation (2-8%) will be administered for anesthesia induction. 2% sevoflurane inhalation will be administered for the maintenance of anesthesia.
Trial: NCT03151863
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine is provided intranasally
Trial: NCT02152332
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg on Day 7 in all treatment sequence.
Trial: NCT02152332
Drug: Moxifloxacin Matched Placebo
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.
Trial: NCT01615198
Drug: Olmesartan
RxNorm normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg, 20 mg, 40 mg capsules
Trial: NCT02268279
Drug: solithromycin
RxNorm normalized name: solithromycin
DrugBank: Solithromycin (DB09308)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03852251
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive AK104 in combination with oxaliplatin and capecitabine.
Trial: NCT00388973
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04284202
Drug: PD-1 plus Dasatinib
RxNorm normalized name: Recombinant pd-1 mab cs1003
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Toripalimub 240mg injection day1; Dasatinib 100mg po qd day1-day21. 3weeks is 1 cycle.
Trial: NCT00575627
Drug: Peg-Interferon alpha2a plus Ribavirin
RxNorm normalized name: PEG-Interferon alfa-2A
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Peg-Interferon alpha2a: 180 micrograms per week Ribavirin:100-1200 mg/daily
Trial: NCT01798589
Drug: Ethylenediamine dihydrochloride allergen patch
RxNorm normalized name: Ethylenediamine
DrugBank: Ethylenediamine (DB14189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 allergen panel containing 2 allergen and 2 control patches
Trial: NCT02833974
Drug: GSK2245035 Nasal Spray Solution
RxNorm normalized name: GSK2245035
DrugBank: GSK2245035 (DB16076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2245035 Nasal Spray Solution 0.2 microgram (mcg)/mL delivering 10 ng GSK2245035 per actuation. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate.
Trial: NCT00407095
Drug: Pardoprunox
RxNorm normalized name: Pardoprunox
DrugBank: Pardoprunox (DB12061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-42 mg/day
Trial: NCT01593293
Drug: Pem only
RxNorm normalized name: methscopolamine nitrate / phenylephrine hydrochloride Extended Release Oral Tablet [Extendryl PEM]
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500mg/m2 intrvenously q 3 weeks till progression or unacceptable toxicity.
Trial: NCT01759940
Drug: ropivacaine 0,375%
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01759940
Drug: ropivacaine 0,75%
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03161054
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction Phase Etoposide: 50 mg/day will be orally administered from day 1 to day 14 (before lunch); Superfrail patients only from cycle 3, 50 mg/day, from day 1 to day 7
Trial: NCT03161054
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction Phase: Rituximab: 375 mg/m2 will be administered by IV infusion up to four infusions on days 8, 15, 22, 29, only in patients suitable for infusion treatment and relapsed after \>6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of Rituximab will not repeat it during the metronomic therapy.
Trial: NCT00355641
Drug: Ropinirole Extended Release (XR)
RxNorm normalized name: ropinirole Extended Release Oral Tablet
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose range of Ropinirole XR of 0.5mg to 6.0mg daily
Trial: NCT00149162
Drug: proleukin
RxNorm normalized name: Proleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One cycle of treatment : D1 : 2.5 MUI/m2 (subcutaneous); D2 to D5 : 5 MUI / m2 (subcutaneous)~1 cycle of treatment each month during 12 months
Trial: NCT00732511
Drug: carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsules in doses of 20, 40, and 80 mg; once daily; 12 weeks duration
Trial: NCT00732511
Drug: metoprolol extended release
RxNorm normalized name: metoprolol Extended Release Oral Tablet
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets in doses 50, 100, and 200 mg; once daily; 12 weeks duration
Trial: NCT01469338
Drug: cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01469338
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01469338
Drug: octreotide pamoate
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IM
Trial: NCT01469338
Drug: octreotide acetate
RxNorm normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given SC
Trial: NCT03902509
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: pirfenidone capsule made in China
Trial: NCT02530528
Drug: CHG
RxNorm normalized name: CHGN111
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varied application times
Trial: NCT03365115
Drug: Intrathecal morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 100 mcg will be injected.
Trial: NCT02897375
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02897375
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02897375
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04193007
Drug: molecular targeted therapies
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: if EGFR mutation is positive, (gefitinib, ecotinib, erlotinib）or ALK/ROS-1 positive（Crizotinib）
Trial: NCT03703882
Drug: Edasalonexent
RxNorm normalized name: Edasalonexent
DrugBank: Edasalonexent (DB15010)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/kg/day
Trial: NCT00625833
Drug: [S,S]-Reboxetine
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet once a day dosing for 10 weeks.
Trial: NCT00747643
Drug: varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in this group received varenicline according to the schedule in the Arm Description.
Trial: NCT00306462
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous magnesium sulfate 6g bolus, then increased by 1 g/hour till a maximum of 5g/hour; gradually wean down to 2 g/hour for a total of 48 hours once uterine contractions is \< 6/hour.
Trial: NCT00306462
Drug: Oral Nifedipine or placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nifedipine or placebo at 20 mg every 30 minutes for the first hour, then 20 mg every 3 to 6 hours not to exceed 180 mg in 24 hours, keep maintenance dose at 20 mg every 3 to 6 hours for a total of 48 hours if uterine contractions is \< 6/hour.
Trial: NCT00003647
Drug: allovectin-7
RxNorm normalized name: Allovectin-7
DrugBank: Allovectin-7 (DB17439)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003647
Drug: allovectin-7/dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003647
Drug: dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001190
Drug: Deslorelin
RxNorm normalized name: deslorelin
DrugBank: Deslorelin (DB11510)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05860075
Drug: IMM01
RxNorm normalized name: IMM01
DrugBank: Timdarpacept (DB17544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMM01 will be administered once a week for 4 weeks.
Trial: NCT01199718
Drug: CX-4945
RxNorm normalized name: CX-046684
DrugBank: CX-046684 (DB19414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CX-4945 capsules, administered orally,as escalating doses. Dose schedule: four times daily for 21 consecutive days every 28 days.
Trial: NCT03555422
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
Trial: NCT03555422
Drug: Matching placebo for selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
Trial: NCT03174275
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive durvalumab, 750 mg every 2 weeks by IV infusion over approximately 1 hour (± 5 minutes).
Trial: NCT03174275
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin is commercially available and approved by the US FDA for use in patients with ovarian cancer.
Trial: NCT03174275
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel is commercially available and approved by the US Food and Drug Administration (FDA) for use in patients with metastatic breast cancer, metastatic pancreatic cancer, and for the treatment of locally advanced or metastatic NSCLC.
Trial: NCT03174275
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin is commercially available and approved by the US Food and Drug Administration (FDA) for the treatment of advanced bladder, ovarian and testicular cancer. It has been widely studied in a variety of solid tumor types.
Trial: NCT02452905
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03824561
Drug: Vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab IV infusion
Trial: NCT02413489
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab 16 mg/kg will be administered as intravenous infusion to participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
Trial: NCT02452905
Drug: Placebo (for Nitazoxanide)
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03321136
Drug: LSD
RxNorm normalized name: LSD
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025 mg LSD per os, single dose
Trial: NCT03321136
Drug: LSD
RxNorm normalized name: LSD
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg LSD per os, single dose
Trial: NCT03321136
Drug: LSD
RxNorm normalized name: LSD
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg LSD per os, single dose
Trial: NCT03321136
Drug: LSD
RxNorm normalized name: LSD
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg LSD per os, single dose
Trial: NCT03321136
Drug: LSD
RxNorm normalized name: LSD
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg LSD plus 40 mg ketanserin per os, single doses each
Trial: NCT02955940
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg BID
Trial: NCT02263079
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive entecavir, either as a film-coated tablet or oral solution, once daily at a dose of 0.015 milligrams per kilogram (mg/kg) (maximum daily dose of 0.5 mg).
Trial: NCT02263079
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive lamivudine, either as a film-coated tablet or oral solution, once daily at a dose of 3 mg/kg (maximum daily dose of 100 mg).
Trial: NCT02263079
Drug: Pegylated Interferon Alfa-2A
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive pegylated interferon-alfa-2A at a body surface area (BSA) based dose of 180 micrograms per 1.73 square meter (mcg/1.73m\^2) BSA.
Trial: NCT02955940
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib at the same dose provided in the parent study at the time of the rollover.
Trial: NCT03527134
Drug: Amantadine
RxNorm normalized name: Amantadine
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive amantadine 100 mg by month 2 h before the induction of general anesthesia and then 100 mg each time, three times per day for 5 days.
Trial: NCT03171220
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine(FLU) 30mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
Trial: NCT01834014
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Trial: NCT04025450
Drug: Chidamide+VRD
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Chidamide:30mg d0,d3,d7,d10/Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14